Cargando…

Mechanism Governing Human Kappa-Opioid Receptor Expression under Desferrioxamine-Induced Hypoxic Mimic Condition in Neuronal NMB Cells

Cellular adaptation to hypoxia is a protective mechanism for neurons and relevant to cancer. Treatment with desferrioxamine (DFO) to induce hypoxia reduced the viability of human neuronal NMB cells. Surviving/attached cells exhibited profound increases of expression of the human kappa-opioid recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Babcock, Jennifer, Herrera, Alberto, Coricor, George, Karch, Christopher, Liu, Alexander H., Rivera-Gines, Aida, Ko, Jane L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297840/ https://www.ncbi.nlm.nih.gov/pubmed/28117678 http://dx.doi.org/10.3390/ijms18010211

Ejemplares similares

Role of human HGFIN/nmb in breast cancer
por: Metz, Rebecca L, et al.
Publicado: (2007)

Distinct roles of NMB and GRP in itch transmission
por: Wan, Li, et al.
Publicado: (2017)

Role of the kringle‐like domain in glycoprotein NMB for its tumorigenic potential
por: Xie, Rudy, et al.
Publicado: (2019)

Desferrioxamine Reduces Oxidative Stress in the Lung Contusion
por: Basaran, Umit Nusret, et al.
Publicado: (2013)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Crystal Structure of Outer Membrane Protein NMB0315 from Neisseria meningitidis
por: Wang, Xiangyu, et al.
Publicado: (2011)

BNP facilitates NMB-encoded histaminergic itch via NPRC-NMBR crosstalk
por: Meng, Qing-Tao, et al.
Publicado: (2021)

Desferrioxamine decreases NAD redox potential of intact red blood cells: evidence for desferrioxamine as an inducer of oxidant stress in red blood cells
por: Niihara, Yutaka, et al.
Publicado: (2002)

Desferrioxamine-related ocular toxicity: A case report
por: Simon, Sumu, et al.
Publicado: (2012)

Tales of the Unexpected: The Case of Zirconium(IV) Complexes with Desferrioxamine
por: Savastano, Matteo, et al.
Publicado: (2019)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

The structure of NMB1585, a MarR-family regulator from Neisseria meningitidis
por: Nichols, Charles E., et al.
Publicado: (2009)

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
por: Aichholzer, Freyja, et al.
Publicado: (2021)

Glycoprotein NMB promotes tumor formation and malignant progression of laryngeal squamous cell carcinoma
por: Manevich, Lev, et al.
Publicado: (2022)

RF19 | PSUN351 Glycoprotein-NMB (GPNMB) is Pro-Tumorigenic in Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2022)

Pharmacological profiles of opioid ligands at Kappa opioid receptors
por: Gharagozlou, Parham, et al.
Publicado: (2006)

Therapeutic Potential of Kappa Opioid Agonists
por: Beck, Tyler C., et al.
Publicado: (2019)

Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4
por: Kaeppeli, Simon A. M., et al.
Publicado: (2019)

(68)Ga-labelled desferrioxamine-B for bacterial infection imaging
por: Petrik, Milos, et al.
Publicado: (2020)

Efficacy of a Validated Yoga Protocol on Dyslipidemia in Diabetes Patients: NMB-2017 India Trial
por: Nagarathna, Raghuram, et al.
Publicado: (2019)

THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker
por: Gibbons, Erin, et al.
Publicado: (2023)

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
por: Hüttenrauch, Melanie, et al.
Publicado: (2018)

Increase of reactive oxygen species by desferrioxamine during experimental Chagas' disease
por: Francisco, Amanda Fortes, et al.
Publicado: (2013)

Phosphorylation of SMC1 by ATR is required for desferrioxamine (DFO)-induced apoptosis
por: So, E Y, et al.
Publicado: (2011)

Pulmonary effects of desferrioxamine in the treatment of an experimental model of fulminant hepatic failure
por: Kalimeris, K, et al.
Publicado: (2007)

Mitochondria-penetrating peptides conjugated to desferrioxamine as chelators for mitochondrial labile iron
por: Alta, Roxana Y. P., et al.
Publicado: (2017)

Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice
por: Wang, Liang, et al.
Publicado: (2017)

Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
por: Peckham, Alyssa M., et al.
Publicado: (2018)

The single-sample network module biomarkers (sNMB) method reveals the pre-deterioration stage of disease progression
por: Zhong, Jiayuan, et al.
Publicado: (2022)

Desferrioxamine Supports Metabolic Function in Primary Human Macrophages Infected With Mycobacterium tuberculosis
por: Phelan, James Joseph, et al.
Publicado: (2020)

Efficacy of desferrioxamine mesylate in intracerebral hematoma: a systemic review and meta-analysis
por: Zhao, Kai, et al.
Publicado: (2022)

Chemoenzymatic Synthesis of Select Intermediates and Natural Products of the Desferrioxamine E Siderophore Pathway
por: Hoffmann, Katherine M., et al.
Publicado: (2022)

Neurons derived from human-induced pluripotent stem cells express mu and kappa opioid receptors
por: Ju, Zhi-Hai, et al.
Publicado: (2020)

Immunolocalization of kappa opioid receptors in the axon initial segment of a group of embryonic mesencephalic dopamine neurons
por: Escobar, Angélica Pilar, et al.
Publicado: (2022)

Structure of the human kappa opioid receptor in complex with JDTic
por: Wu, Huixian, et al.
Publicado: (2012)

Identification of novel ligands interacting with kappa opioid receptors
por: Spetea, Mariana, et al.
Publicado: (2011)

Cardiorenal Effects of Kappa Opioid Peptides During Ontogeny
por: Smith, Francine G., et al.
Publicado: (2011)

Major Depressive Disorder and Kappa Opioid Receptor Antagonists
por: Li, Wei, et al.
Publicado: (2016)

Kappa Opioids, Salvinorin A and Major Depressive Disorder
por: Taylor, George T., et al.
Publicado: (2016)

The Kappa Opioid Receptor: From Addiction to Depression, and Back
por: Lalanne, Laurence, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p7hktoomdscts8ag69m9h7u82e